AstraZeneca Inks Deal - Analyst Blog

By
A A A

AstraZeneca ( AZN ) recently entered into a research collaboration with a Russia-based institute, N.N. Petrov institute of oncology for identification of genetic mutations in patients suffering from cancer.

As per the terms of the agreement, teams from AstraZeneca's oncology innovative medicines group will work with scientists from Petrov Institute at various centers across the globe.

We are positive on Astrazeneca's deal with the Russian institute. It reflects the company's efforts to boost/develop its pipeline. We believe that AstraZeneca's pipeline must deliver since many of its drugs are facing/likely to face generic competition

Generic competition has adversely impacted AstraZeneca's revenues over the past few quarters. 2013 is expected to be a challenging year for AstraZeneca. The company expects mid-to-high single-digit decline in revenues in 2013 primarily due to generic erosion of Seroquel IR and Crestor (in Canada) revenues.

This has put significant pressure on the company. Additionally, there is increasing uncertainty regarding the company's key drug Crestor (cholesterol management) due to the entry of generic versions of a competitor drug. The company's much hyped antiplatelet, Brilinta's performance has remained lukewarm.

AstraZeneca is looking to combat the generic threat through deals and acquisitions. The Ardelyx and Isis Pharma agreements, Ardea acquisition, the collaboration with Amgen ( AMGN ) and the expansion of the diabetes alliance with Bristol-Myers Squibb Company ( BMY ) represent efforts in that direction.

AstraZeneca carries a Zacks Rank #3 (Hold). However, other large cap pharma stocks such as Bayer ( BAYRY ) currently look more attractive with a Zacks Rank #2 (Buy).



AMGEN INC (AMGN): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

BAYER A G -ADR (BAYRY): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AMGN , AZN , BAYRY , BMY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com